Balint Bettina, Bhatia Kailash P
aSobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London, UK bDepartment of Neurology, University Hospital, Heidelberg, Germany.
Curr Opin Neurol. 2014 Aug;27(4):468-76. doi: 10.1097/WCO.0000000000000114.
This article will highlight recent advances in dystonia with focus on clinical aspects such as the new classification, syndromic approach, new gene discoveries and genotype-phenotype correlations. Broadening of phenotype of some of the previously described hereditary dystonias and environmental risk factors and trends in treatment will be covered.
Based on phenomenology, a new consensus update on the definition, phenomenology and classification of dystonia and a syndromic approach to guide diagnosis have been proposed. Terminology has changed and 'isolated dystonia' is used wherein dystonia is the only motor feature apart from tremor, and the previously called heredodegenerative dystonias and dystonia plus syndromes are now subsumed under 'combined dystonia'. The recently discovered genes ANO3, GNAL and CIZ1 appear not to be a common cause of adult-onset cervical dystonia. Clinical and genetic heterogeneity underlie myoclonus-dystonia, dopa-responsive dystonia and deafness-dystonia syndrome. ALS2 gene mutations are a newly recognized cause for combined dystonia. The phenotypic and genotypic spectra of ATP1A3 mutations have considerably broadened. Two new genome-wide association studies identified new candidate genes. A retrospective analysis suggested complicated vaginal delivery as a modifying risk factor in DYT1. Recent studies confirm lasting therapeutic effects of deep brain stimulation in isolated dystonia, good treatment response in myoclonus-dystonia, and suggest that early treatment correlates with a better outcome.
Phenotypic classification continues to be important to recognize particular forms of dystonia and this includes syndromic associations. There are a number of genes underlying isolated or combined dystonia and there will be further new discoveries with the advances in genetic technologies such as exome and whole-genome sequencing. The identification of new genes will facilitate better elucidation of pathogenetic mechanisms and possible corrective therapies.
本文将重点介绍肌张力障碍的最新进展,聚焦于临床方面,如新分类、综合征方法、新基因发现以及基因型-表型相关性。还将涵盖一些先前描述的遗传性肌张力障碍的表型扩展、环境危险因素及治疗趋势。
基于现象学,已提出关于肌张力障碍定义、现象学和分类的新共识更新以及指导诊断的综合征方法。术语发生了变化,使用了“孤立性肌张力障碍”,即除震颤外肌张力障碍是唯一的运动特征,先前所称的遗传退行性肌张力障碍和肌张力障碍叠加综合征现归入“合并性肌张力障碍”。最近发现的ANO3、GNAL和CIZ1基因似乎并非成人起病型颈部肌张力障碍的常见病因。肌阵挛性肌张力障碍、多巴反应性肌张力障碍和耳聋-肌张力障碍综合征存在临床和遗传异质性。ALS2基因突变是合并性肌张力障碍新认识到的病因。ATP1A3突变的表型和基因型谱已大幅拓宽。两项新的全基因组关联研究确定了新的候选基因。一项回顾性分析表明复杂阴道分娩是DYT1型肌张力障碍的一个修饰性危险因素。近期研究证实了深部脑刺激对孤立性肌张力障碍的持久治疗效果、对肌阵挛性肌张力障碍的良好治疗反应,并表明早期治疗与更好的预后相关。
表型分类对于识别特定形式的肌张力障碍仍然很重要,这包括综合征关联。孤立性或合并性肌张力障碍有多种潜在基因,随着外显子组和全基因组测序等基因技术的进步,还会有更多新发现。新基因的鉴定将有助于更好地阐明发病机制和可能的矫正治疗方法。